Evidence map›Paper›PMID 37941005›Full record

ArticleCancer cell international2023

Interplay between lncRNA RP11-367G18.1 variant 2 and YY1 plays a vital role in hypoxia-mediated gene expression and tumorigenesis.

Pei-Hua Peng, Ji-Lin Chen, Heng-Hsiung Wu, Wen-Hao Yang, Li-Jie Lin, Joseph Chieh-Yu Lai, Jeng-Shou Chang, Jia-Ling Syu, Han-Tsang Wu, Fei-Ting Hsu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Pei-Hua Peng *Cancer Genome Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, 333, Taiwan.
Ji-Lin Chen *Comprehensive Breast Health Center, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih- Pai Road, Taipei, 112, Taiwan.
Heng-Hsiung Wu *Research Center for Cancer Biology, China Medical University, Taichung, 40402, Taiwan.
Wen-Hao Yang *Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 40402, Taiwan.
Li-Jie LinResearch Center for Cancer Biology, China Medical University, Taichung, 40402, Taiwan.
Joseph Chieh-Yu LaiInstitute of Biomedical Science, China Medical University, Taichung, 40402, Taiwan.
Jeng-Shou ChangCancer Genome Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, 333, Taiwan.
Jia-Ling SyuResearch Center for Cancer Biology, China Medical University, Taichung, 40402, Taiwan.
Han-Tsang WuCancer Research Center, Changhua Christian Hospital, Changhua, 500, Taiwan.
Fei-Ting HsuDepartment of Biological Science and Technology, China Medical University, Taichung, 40402, Taiwan. Sakiro920@gmail.com.
Wei-Chung ChengResearch Center for Cancer Biology, China Medical University, Taichung, 40402, Taiwan. wccheng@mail.cmu.edu.tw.
Kai-Wen HsuResearch Center for Cancer Biology, China Medical University, Taichung, 40402, Taiwan. kwhsu@mail.cmu.edu.tw.
China Medical University · TWChang Gung Memorial Hospital · TWChina Medical University Hospital · TWTaipei Veterans General Hospital · TW

Funding

Ministry of Science and Technology, Taiwan MOST 111-2314-B-182A-034Ministry of Science and Technology, Taiwan MOST 111-2628-B-039-007-MY3
6 · The paper itself

Abstract

backgroundThe hypoxia-responsive long non-coding RNA, RP11-367G18.1, has recently been reported to induce histone 4 lysine 16 acetylation (H4K16Ac) through its variant 2; however, the underlying molecular mechanism remains poorly understood.

methodsRNA pull-down assay and liquid chromatography-tandem mass spectrometry were performed to identify RP11-367G18.1 variant 2-binding partner. The molecular events were examined utilizing western blot analysis, real-time PCR, luciferase reporter assay, chromatin immunoprecipitation, and chromatin isolation by RNA purification assays. The migration, invasion, soft agar colony formation, and in vivo xenograft experiments were conducted to evaluate the impact of RP11-367G18.1 variant 2-YY1 complex on tumor progression.

resultsIn this study, RNA sequencing data revealed that hypoxia and RP11-367G18.1 variant 2 co-regulated genes were enriched in tumor-related pathways. YY1 was identified as an RP11-367G18.1 variant 2-binding partner that activates the H4K16Ac mark. YY1 was upregulated under hypoxic conditions and served as a target gene for hypoxia-inducible factor-1α. RP11-367G18.1 variant 2 colocalized with YY1 and H4K16Ac in the nucleus under hypoxic conditions. Head and neck cancer tissues had higher levels of RP11-367G18.1 and YY1 which were associated with poor patient outcomes. RP11-367G18.1 variant 2-YY1 complex contributes to hypoxia-induced epithelial-mesenchymal transition, cell migration, invasion, and tumorigenicity. YY1 regulated hypoxia-induced genes dependent on RP11-367G18.1 variant 2.

conclusionsRP11-367G18.1 variant 2-YY1 complex mediates the tumor-promoting effects of hypoxia, suggesting that this complex can be targeted as a novel therapeutic strategy for cancer treatment.

Indexed as

HypoxialncRNA RP11-367G18.1 variant 2YY1

Identifiers

PMID37941005
PMCPMC10634066
OpenAlexW4388488658

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.